Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001179110-20-003307)

Filing Details

Accession Number:: 0001179110-20-003307
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-09 17:12:47
Reporting Period:: 2020-03-05

Accepted Time:: 2020-03-09 17:12:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1235010	Momenta Pharmaceuticals Inc	MNTA	Biological Products, (No Disgnostic Substances) (2836)	043561634

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1706857	Santiago Arroyo	C/O Momenta Pharmaceuticals, Inc. 301 Binney Street Cambridge MA 02142	Svp, Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-05	15,000	$0.00	34,576	No	4	A	Direct
Common Stock	Disposition	2020-03-06	7,356	$28.97	27,220	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Acquisiton	2020-03-05	15,000	$0.00	15,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,000			No	4	A	Direct

Footnotes

Shares received pursuant to settlement of Performance Stock Units that were granted on October 17, 2018.
This transaction was effected pursuant to a Rule 10b5-1 trading plan.
Each Restricted Stock Unit represents a contingent right to receive one share of MNTA Common Stock.
Subject to the officer's continued employment with the company, the Restricted Stock Units will vest on March 5, 2021.